Peter Kristensen - Genmab AS Director, Employee Representative
| GNMSF Stock | USD 289.74 13.27 4.80% |
Director
Mr. Peter Storm Kristensen has served as Director, Employee Representative at Genmab AS since March 17, 2016. He has broad legal experience within the pharmaceutical industry with specialty in corporate law, securities law, human resources law as well as drafting and negotiating contracts in general. He is Associate Director, Legal at Genmab. since 2016.
| Age | 43 |
| Tenure | 8 years |
| Phone | 45 70 20 27 28 |
| Web | https://www.genmab.com |
Genmab AS Management Efficiency
The company has return on total asset (ROA) of 0.1029 % which means that it generated a profit of $0.1029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2359 %, meaning that it generated $0.2359 on every $100 dollars invested by stockholders. Genmab AS's management efficiency ratios could be used to measure how well Genmab AS manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Bassil Dahiyat | Kodiak Sciences | 47 | |
| Nancy Hawthorne | Tscan Therapeutics | 66 | |
| David Barrett | Fortress Biotech Pref | 39 | |
| Jane Nelson | Tscan Therapeutics | N/A | |
| David Downes | Tscan Therapeutics | 76 | |
| Richard Levy | Kodiak Sciences | 60 | |
| Someit MD | Zura Bio Limited | 34 | |
| Robert Profusek | Kodiak Sciences | 68 | |
| Admiral Giambastiani | Tscan Therapeutics | N/A | |
| David Southwell | Tscan Therapeutics | 63 | |
| Deborah McAneny | Tscan Therapeutics | 58 | |
| Keith Hughes | Tscan Therapeutics | 70 | |
| Kevin Lorenz | Fortress Biotech Pref | N/A | |
| Malcolm Hoenlein | Fortress Biotech Pref | 73 | |
| Felix Baker | Kodiak Sciences | 49 | |
| Jimmie Harvey | Fortress Biotech Pref | 62 | |
| Jay Lobell | Fortress Biotech Pref | 51 | |
| James Kern | Tscan Therapeutics | 49 | |
Management Performance
Genmab AS Leadership Team
Elected by the shareholders, the Genmab AS's board of directors comprises two types of representatives: Genmab AS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genmab. The board's role is to monitor Genmab AS's management team and ensure that shareholders' interests are well served. Genmab AS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genmab AS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Birgitte Stephensen, Senior Vice President IPR and Legal | ||
| Birgitte MSc, Ex Officer | ||
| Daniel Bruno, Director, Employee Representative | ||
| Peter Kristensen, Director, Employee Representative | ||
| Nedjad Losic, Director, Employee Representative | ||
| David Eatwell, CFO and Executive VP | ||
| Anthony Mancini, Ex COO | ||
| Paolo Paoletti, Director | ||
| Michael Bauer, Senior Vice President Clinical Development | ||
| Anthony Pagano, Senior Vice President Global Finance | ||
| Martine Vugt, Senior Vice President Strategic Initiatives | ||
| Andrew Carlsen, Senior Director, Investor Relations | ||
| Paul Parren, Sr. VP and Scientific Director | ||
| Tom Vink, Director, Employee Representative | ||
| Mijke Zachariasse, Director Director | ||
| Rick Hibbert, Director, Employee Representative | ||
| Pernille Erenbjerg, Director | ||
| Mats Pettersson, Chairman of the Board | ||
| Marisol Peron, Corporate Vice President Communications and Investor Relations | ||
| Rolf Hoffman, Independent Director | ||
| Rachel Gravesen, Senior Vice President Investor Relations and Communications | ||
| Burton Malkiel, Independent Director | ||
| Deirdre Connelly, Director | ||
| Judith Klimovsky, Executive Vice President Chief Development Officer | ||
| Tahamtan Ahmadi, Senior Vice President Oncology and Translational Medicine | ||
| Judith MD, Exec Officer | ||
| Anders Pedersen, Deputy Chairman of the Board | ||
| Rolf Hoffmann, Director | ||
| Peter Ros, Sr Accounting | ||
| Jan Winkel, President and CEO | ||
| Rima Nassar, Head VP |
Genmab Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Genmab AS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.24 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.47 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 26.41 B | |||
| Shares Outstanding | 65.96 M | |||
| Shares Owned By Institutions | 49.90 % | |||
| Price To Earning | 39.08 X | |||
| Price To Book | 7.94 X | |||
| Price To Sales | 2.45 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Genmab Pink Sheet please use our How to Invest in Genmab AS guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Genmab Pink Sheet analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |